WO2003030915A1 - Use of solamargine for treating skin tumors - Google Patents
Use of solamargine for treating skin tumors Download PDFInfo
- Publication number
- WO2003030915A1 WO2003030915A1 PCT/EP2002/011318 EP0211318W WO03030915A1 WO 2003030915 A1 WO2003030915 A1 WO 2003030915A1 EP 0211318 W EP0211318 W EP 0211318W WO 03030915 A1 WO03030915 A1 WO 03030915A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solamargine
- use according
- skin tumors
- treating skin
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to the use of the triglycoside solamargine (22R, 25R)- spiro-5-en-3 ⁇ -yl- ⁇ -L-rhamnopyranosyl-(1 ⁇ 2glu)- ⁇ -L-rhamnopyranosyl-(1 ⁇ 4glu)- ⁇ - D-gluco-pyranose for the preparation of pharmaceutical compositions for treating skin tumors.
- compositions according to the invention are useful for the treatment of human skin tumors, like premalignant skin lesions, malignant skin lesions.
- malignant skin tumors like basal cell carcinomas (BCCs), squamous cell carcinomas (SCCs), Karposi's sarcoma and benign skin tumors like actinic keratosis, keratoses and keratoacanthomas.
- BCCs basal cell carcinomas
- SCCs squamous cell carcinomas
- Karposi's sarcoma and benign skin tumors like actinic keratosis, keratoses and keratoacanthomas.
- BEC is incorporated in small concentrations into an over the counter (OTC) topical formulation (Curaderm®), which is used to treat skin lesions such as sunspots and keratosis.
- OTC over the counter topical formulation
- the present invention is directed to the use of the solasodine triglycoside solamargine for the preparation of pharmaceutical compositions for treating skin tumors.
- BCCs basal cell carcinomas
- SCCs squamous cell carcinomas
- Karposi's sarcoma benign tumors.like actinic keratosis, keratoses and keratoacanthomas even in the absence of the other solasodine glycoside components. Since it is well recognized in the art that the effect of plant extract is very often caused by the often complex interactions and potentating effects of the individual compounds present in crude plant extracts comprising more than 1 potentially active component this finding was very unexpected.
- the invention provides a novel, more stable, fully characterized, effective pharmaceutical composition for treating skin tumors, benign as well as malignant tumors.
- compositions of the invention may be administered e. g. orally, parenterally, topically or via an implanted reservoir or therapeutic system, whereby parenteral or topical administration are preferred. Particularly preferred is the topical administration.
- Sterile injectable compositions according to the invention may be aqueous or oleagious formulation.
- formulations may be formulated according to techniques well known in the art using suitable solvents, diluents or vehicles such as water for injection, Ringer's solution and isotonic sodium chloride solution.
- suitable solvents such as water for injection, Ringer's solution and isotonic sodium chloride solution.
- adjuvants may also be used.
- the pharmaceutical compositon of the invention may also be orally administered in any orally acceptable dosage form, including capsules, tablets, granules, suspensions or solutions, which are also formulated according techniques well known in the art.
- the formulation may be in suitable formulations such as cremes, gels, ointments, liniments, lotions, emulsions and patches using suitable carriers and adjuvants well known in the art.
- compositions especially the compositions for topical administration should be formulated to comprise between 0.001 and 10% (w/w), 0.001 and 4% (w/w)) preferably between 0.001 and 1% (w/w) and most preferably between 0.001% and 0.5% (w/w) of the formulation.
- a specific dosage and treatment regimen will depended upon variety of factors such as e. g. age, bodyweight, general state of health, sex of the patient, severity of disease and concommitant medication.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01124056.1 | 2001-10-09 | ||
EP01124056 | 2001-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003030915A1 true WO2003030915A1 (en) | 2003-04-17 |
Family
ID=8178896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/011318 WO2003030915A1 (en) | 2001-10-09 | 2002-10-09 | Use of solamargine for treating skin tumors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003030915A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8614196B2 (en) | 2011-05-12 | 2013-12-24 | G & E Herbal Biotechnology Co., Ltd. | Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water-soluble extract from plant of Solanum genus |
CN114848663A (en) * | 2022-05-09 | 2022-08-05 | 河南省人民医院 | Application of natural compound Solamargine and anti-HBV (hepatitis B virus) pharmaceutical composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU540812B2 (en) * | 1979-05-02 | 1984-12-06 | Aruba Qld Pty. Ltd. | Steroid alkaloids |
WO1991010743A1 (en) * | 1990-01-18 | 1991-07-25 | Cura Nominees Pty Ltd | Glycoalkaloids |
WO2000061153A1 (en) * | 1999-04-09 | 2000-10-19 | Cura Nominees Pty. Ltd. | Medicinal compositions and their method of preparation |
US6214803B1 (en) * | 1999-08-25 | 2001-04-10 | Committee On Chinese Medicine And Pharmacy Department Of Health Executive Yuan | Pharmacological composition for treating cancer cells |
-
2002
- 2002-10-09 WO PCT/EP2002/011318 patent/WO2003030915A1/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU540812B2 (en) * | 1979-05-02 | 1984-12-06 | Aruba Qld Pty. Ltd. | Steroid alkaloids |
WO1991010743A1 (en) * | 1990-01-18 | 1991-07-25 | Cura Nominees Pty Ltd | Glycoalkaloids |
WO2000061153A1 (en) * | 1999-04-09 | 2000-10-19 | Cura Nominees Pty. Ltd. | Medicinal compositions and their method of preparation |
US6214803B1 (en) * | 1999-08-25 | 2001-04-10 | Committee On Chinese Medicine And Pharmacy Department Of Health Executive Yuan | Pharmacological composition for treating cancer cells |
Non-Patent Citations (4)
Title |
---|
CHAM B E ET AL: "TOPICAL TREATMENT OF MALIGNANT AND PREMALIGNANT SKIN LESIONS BY VERY LOW CONCENTRATIONS OF A STANDARD MIXTURE (BEC) OF SOLASODINE GLYCOSIDES", CANCER LETTERS, NEW YORK, NY, US, vol. 59, 1991, pages 183 - 192, XP001077064, ISSN: 0304-3835 * |
CHAM B E: "SOLASODINE GLYCOSIDES AS ANTI-CANCER AGENTS: PRE-CLINICAL AND CLINICAL STUDIES", ASIA PACIFIC JOURNAL OF PHARMACOLOGY, SINGAPORE UNIVERSITY PRESS, SG, vol. 9, 1994, pages 113 - 118, XP002950616, ISSN: 0217-9687 * |
CHEM B E ET AL: "GLYCOALKALOIDS FROM SOLANUM SODOMAEUM ARE EFFECTIVE IN THE TREATMENT OF SKIN CANCERS IN MAN", CANCER LETTERS, NEW YORK, NY, US, vol. 36, 1987, pages 111 - 118, XP002950615, ISSN: 0304-3835 * |
DAUNTHER B ET AL: "SOLASODINE GLYCOSIDES. IN VITRO PREFERENTIAL CYTOTOXICITY FOR HUMAN CANCER CELLS", CANCER LETTERS, NEW YORK, NY, US, vol. 55, 1990, pages 209 - 220, XP002950612, ISSN: 0304-3835 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8614196B2 (en) | 2011-05-12 | 2013-12-24 | G & E Herbal Biotechnology Co., Ltd. | Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water-soluble extract from plant of Solanum genus |
CN114848663A (en) * | 2022-05-09 | 2022-08-05 | 河南省人民医院 | Application of natural compound Solamargine and anti-HBV (hepatitis B virus) pharmaceutical composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023158064A (en) | Crude drug-containing pharmaceutical composition | |
HU197840B (en) | Process for producing synergic pharmaceutical compositions comprising amantadin and selegilin | |
EP0300282A1 (en) | Pharmaceutical and cosmetic compositions containing complexes of flavanolignans with phospholipids | |
US11007241B2 (en) | Compositions for relieving pain with malkangni oil and cypriol oil as active ingredients and method of topical administration of the same | |
US7115563B2 (en) | Composition and its therapeutic use | |
AU2002231095B2 (en) | Method and composition for the treatment of diabetic neuropathy | |
JPH05286864A (en) | Pharmaceutical preparation for topical use in treatment of psoriasis and atopical dermatitis | |
OA12862A (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone. | |
JPS61205272A (en) | Novel tannin | |
RU2566065C2 (en) | Garcinol and cyclodextrin complex and method of its application | |
WO2003030915A1 (en) | Use of solamargine for treating skin tumors | |
WO2003030884A2 (en) | Use of solasonine for the treatment of skin tumors | |
CN110709087A (en) | Skin problem inhibitor and composition for inhibiting skin problems | |
Sekhar et al. | A review on anticancer potential of natural drugs: hispolon and limonene | |
US20120201903A1 (en) | Cytoprotective or therapeutic plant composition | |
KR100227095B1 (en) | Anti-hiv agent | |
EP3166604B1 (en) | Substances for the treatment of retroviral infectious diseases | |
DE60219620T2 (en) | L-ASCORBIC ACID 2-O-MALEIC ACID-A-TOCOPHEROLDIESTER-1-PROPANOL ADDUCT AND METHOD FOR THE PRODUCTION THEREOF | |
KR20200025244A (en) | Composition for preventing, alleviating or treating pruritus, containing punicalagin | |
EP3558266B1 (en) | Altertoxin ii as a selective inhibitor of ewing family of tumor cells | |
JPH06199675A (en) | Antiinflammatory and antipruritic agent composition | |
JPH04108736A (en) | Virus-genomic inactivating-carcinogenic promotion inhibitor | |
JP2600786B2 (en) | Hair restorer | |
JP7229678B2 (en) | External pharmaceutical composition | |
US6277834B1 (en) | Agents for relieving side effects of adrenal cortex hormone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |